REG-4basebio Plc: Director/PDMR Shareholding

4BasebioAnnouncement

11/05/2022 12:00

11 May 2022

4basebio plc
(the "Company")
 

Director’s Dealing

4basebio PLC (AIM: 4BB), the specialist life sciences group focused on
exploiting intellectual property in the field of cell and gene therapies and
DNA vaccines, announces that, on 09 May 2022, Heikki Lanckriet, chief
executive officer, acquired 500 ordinary shares at a price of 500 pence per
share.

As a result of the acquisition of ordinary shares, Heikki Lanckriet’s
beneficial holding, including shares held by persons closely associated with
him, comprises 1,249,453 ordinary shares representing 10.14 per cent. of the
Company’s issued share capital.

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014.

For further enquiries, please contact:

 4basebio plc                                        +44 (0)12 2396 7943 
 Heikki Lanckriet, CEO                                                   
                                                                         
 Cairn Financial Advisers LLP (Nominated Adviser )   +44 (0)20 7213 0880 
 Jo Turner / Sandy Jamieson                                              
                                                                         
 finnCap Ltd (Broker)                                +44 (0)20 7220 0500 
 Geoff Nash/Richard Chambers/Charlotte Sutcliffe                         
                                                                         

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014

1.        Details of the person discharging managerial
responsibilities/person closely associated

a.        Name                     
                              Heikki Lanckriet

2.        Reason for notification

a.        Position/Status                   
               Chief Executive Officer

b.        Initial notification/ Amendment    Initial

3.        Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor

a.        Name
                                                  
4basebio plc

b.        LEI
                                                        
213800E2DX9EAIUNCB30

4.        Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted

a.        Description of the financial instrument, type Ordinary Shares
of instrument

Identification Code                            ISIN:
GB00BMCLYF79
 

b.        Nature of the transaction               
Acquisition of ordinary shares
 

c.         Price(s) and volume(s)       Volume(s)
          Price (p)
 

500 500p

d.        Aggregated information  

- Aggregated Volume                        500
-
Price                                    
               500 pence per share
 

e.        Date of the transaction                   
09/05/2022
 

f.         Place of the transaction London Stock Exchange, AIM



Copyright (c) 2022 PR Newswire Association,LLC. All Rights Reserved